Aragen Operationalizes First Phase of Biologics Manufacturing Unit in India

Engineering Aragen Operationalizes First Phase of Biologics Manufacturing Unit in India

2024-03-28 Source: Press release Aragen 2 min Reading Time

Related Vendors

Glatt Ingenieurtechnik GmbH

Italvacuum, Srl

Angst+Pfister AG

The leading Contract Research Development and Manufacturing Organization for small molecules and biologics Aragen has invested 30 million dollars for setting up the biologics manufacturing facility in Bangalore, India. The firm has successfully operationalized the first phase of this facility.

Aragen's biologics manufacturing facility in India. (Source: Aragen) — Aragen's biologics manufacturing facility in India.
(Source: Aragen)

Hyderabad/India – Aragen, a leading Contract Research Development and Manufacturing Organization (CRDMO) for small molecules and biologics, has operationalized the first phase of its biologics manufacturing facility in Bangalore, India through its 100 % subsidiary, Aragen Biologics. The facility is being set up at an investment of 30 million dollars. It has also executed its first small-scale manufacturing project for a US-based organization for manufacturing a novel anticancer monoclonal antibody. The non-GMP facility can undertake batch sizes upto 50 Ltrs and includes process development and analytical labs to support the manufacturing activities.

Commenting on the occasion, Manni Kantipudi, CEO Aragen Life Sciences and Director of Aragen Biologics said, “We are happy to announce the commissioning of the first phase of our biologics manufacturing facility at Bangalore, India as per schedule and the successful completion of the first project at this facility. This brings us one step closer to offering full-scale Gene-to GMP solutions to our customers. Once the facility’s expansion is fully operational by the end of this calendar year, we will be able to do internal tech transfer from our R&D labs in California to the manufacturing site in India, thereby enabling end-to-end integrated service offering to customers.”

Aragen currently offers discovery and development research services from its R&D labs in California, USA. Services include cell line development, upstream and downstream development, protein science, and antibody discovery. The biologics manufacturing facility at Bangalore will complement these services and will enable GMP and non-GMP manufacturing. It will have advanced single-use bioreactors with capacities ranging from 50 Ltr to 2000 Ltrs and will offer integrated solutions including process development, process validation, analytical development, small-scale manufacturing, large-scale DS manufacturing and stability services. It will have the capability to develop and manufacture monoclonal antibodies, therapeutic proteins and fusion proteins to augment the company’s bioproduction capability in California.

(ID:49980640)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Business E-mail

Please enter a valid mailadress.

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Date: 08.12.2025

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planck-Str. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

Additionally, my consent also includes the processing of my email address and telephone number for data matching for marketing purposes with select advertising partners such as LinkedIn, Google, and Meta. For this, Vogel Communications Group may transmit said data in hashed form to the advertising partners who then use said data to determine whether I am also a member of the mentioned advertising partner portals. Vogel Communications Group uses this feature for the purposes of re-targeting (up-selling, cross-selling, and customer loyalty), generating so-called look-alike audiences for acquisition of new customers, and as basis for exclusion for on-going advertising campaigns. Further information can be found in section “data matching for marketing purposes”.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here. This does not apply to data matching for marketing purposes.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://contact.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.